Adicet Bio, Inc. (ACET) Stock Score, Valuation & Financial Research

Adicet Bio, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for ACET

Adicet Bio, Inc. does not currently have a complete Wall Street Score. The stored market price is USD 6.25. These figures are a research snapshot, not a buy or sell recommendation.

What Adicet Bio, Inc. does

Adicet Bio, Inc. is a biotechnology firm dedicated to pioneering allogeneic gamma delta T cell therapies, aiming to treat cancer and various other diseases. The company’s strategy involves engineering gamma delta T cells with chimeric antigen receptors (CARs) and T cell receptor-like antibodies. This advanced modification is designed to achieve more precise targeting of tumors, enhance the body's natural and acquired immune responses against cancer, and provide sustained therapeutic benefits for patients. ADI-001, its most advanced therapeutic candidate, is presently in a Phase I clinical trial for individuals with non-Hodgkin's lymphoma. Additionally, Adicet Bio is developing ADI-002, which is undergoing preclinical investigations for its potential in treating a range of solid tumors. The company is headquartered in Boston, Massachusetts.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Adicet Bio is a clinical-stage biotechnology company focused on the discovery and development of allogeneic gamma delta T cell therapies for cancer and other diseases. The company currently operates as a research and development entity and has not yet generated revenue from product sales, relying instead on capital raises and potential future licensing or collaboration agreements to fund its operations.

Products and services

  • The company is developing a pipeline of off-the-shelf allogeneic gamma delta T cell therapies, including lead candidates such as ADI-001 and ADI-212, designed to target various hematologic malignancies and solid tumors.

Customer types

Clinical trial patients.

Suppliers, materials and equipment

  • Contract Manufacturing Organizations (CMOs) — The company relies on third-party contract manufacturing organizations for the production of clinical trial materials and drug products; specific supplier names are not disclosed. Source

Competitors and product-market comparisons

  • Allogene Therapeutics, Inc. — Competes in the development of allogeneic CAR T cell therapies. Source
  • CRISPR Therapeutics AG — Competes in the development of gene-edited cell therapies. Source

Business strengths to evaluate

  • Proprietary gamma delta T cell platform technology Source

Business risks and research considerations

  • History of operating losses and expectation of future losses Source
  • Dependence on third-party manufacturers for clinical supply Source

Sources: Company research source

Company research refreshed 2026-10-12. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

ACET financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 6.25
Market capitalization:
58.43M (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -98.97M
Free cash flow:
USD -96.98M
Cash:
USD 33.13M
Total debt:
USD 12.85M
EPS:
USD -11.45

What stands out

  • Free cash flow is USD -96.98M, negative for the stored period.
  • The balance sheet shows USD 33.13M of cash versus USD 12.85M of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 20.28M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for ACET

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can ACET fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is ACET likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for ACET to reach sustainable profitability?
  • What does the current fundamental change risk warning mean for the reliability or interpretation of ACET's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 73% of the scoring inputs required for this public page are currently available.

How to research ACET

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.